HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
USFDA concludes inspection at Haleos Labs’ arm’s Andhra Pradesh facility
Sep-18-2026

The United States Food and Drug Administration (USFDA) has concluded inspection at Haleos Labs’ Material Subsidiary-- Mahi Drugs’ API manufacturing facility located at Plot No. 82, Jawaharlal Nehru Pharma City, parawada, Anakapalli, Andhra Pradesh. The inspection was conducted from September 15, 2026 to September 18, 2026. 

The inspection concluded with zero Form 483 observations, thereby achieving the same outcome as the previous USFDA inspection conducted at the said facility in January 2025. This outcome reflects the company's continued commitment to maintaining the highest standards of regulatory compliance, quality and operational excellence. 

Haleos Labs (formerly known as SMS Lifesciences India) is presently engaged in the business of manufacturing, buying, selling, offering consultancy, importing and exporting, acting as commission agents and generally dealing with of all types of Organic & Inorganic Chemicals, Pharmaceuticals, API and Intermediates. 


  RELATED NEWS >>